XML 46 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9
Collaboration and License Agreements, Takeda Pharmaceutical Company Limited (Details) (USD $)
1 Months Ended 3 Months Ended
May 31, 2014
Mar. 31, 2015
Dec. 31, 2014
License And Collaboration Agreements [Line Items]      
Non-refundable upfront payment $ 15,000,000mgnx_NonRefundableUpfrontFees    
Deferred revenue current   12,382,000us-gaap_DeferredRevenueCurrent 14,248,000us-gaap_DeferredRevenueCurrent
Deferred revenue non-current   14,389,000us-gaap_DeferredRevenueNoncurrent 16,472,000us-gaap_DeferredRevenueNoncurrent
Takeda Pharmaceutical Company Limited [Member]      
License And Collaboration Agreements [Line Items]      
Collaboration agreement date   May 2014  
License option fee   15,000,000mgnx_PotentialLicenseOptionFee
/ us-gaap_CounterpartyNameAxis
= mgnx_TakedaPharmaceuticalMember
 
Upfront fee allocated to agreement   10,000,000mgnx_UpfrontFeeAllocatedToAgreement
/ us-gaap_CounterpartyNameAxis
= mgnx_TakedaPharmaceuticalMember
 
Expected period of development   24 months  
Recognized revenue under agreement   4,300,000us-gaap_LicensesRevenue
/ us-gaap_CounterpartyNameAxis
= mgnx_TakedaPharmaceuticalMember
 
Deferred revenue   5,800,000us-gaap_DeferredRevenue
/ us-gaap_CounterpartyNameAxis
= mgnx_TakedaPharmaceuticalMember
7,100,000us-gaap_DeferredRevenue
/ us-gaap_CounterpartyNameAxis
= mgnx_TakedaPharmaceuticalMember
Deferred revenue current   5,000,000us-gaap_DeferredRevenueCurrent
/ us-gaap_CounterpartyNameAxis
= mgnx_TakedaPharmaceuticalMember
5,000,000us-gaap_DeferredRevenueCurrent
/ us-gaap_CounterpartyNameAxis
= mgnx_TakedaPharmaceuticalMember
Deferred revenue non-current   800,000us-gaap_DeferredRevenueNoncurrent
/ us-gaap_CounterpartyNameAxis
= mgnx_TakedaPharmaceuticalMember
2,100,000us-gaap_DeferredRevenueNoncurrent
/ us-gaap_CounterpartyNameAxis
= mgnx_TakedaPharmaceuticalMember
Revenue Recognition, Milestone Method, Revenue Recognized   3,000,000us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
/ us-gaap_CounterpartyNameAxis
= mgnx_TakedaPharmaceuticalMember
 
Additional Potential Sales Milestone Payments Under Agreement   375,500,000mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement
/ us-gaap_CounterpartyNameAxis
= mgnx_TakedaPharmaceuticalMember
 
Additional Potential Clinical And Regulatory Milestone Payments Under Agreement   93,000,000mgnx_AdditionalPotentialClinicalAndRegulatoryMilestonePaymentsUnderAgreement
/ us-gaap_CounterpartyNameAxis
= mgnx_TakedaPharmaceuticalMember
 
Takeda Pharmaceutical Company Limited [Member] | Research Collaboration And License Option Agreement [Member]      
License And Collaboration Agreements [Line Items]      
Upfront fee allocated to agreement   5,000,000mgnx_UpfrontFeeAllocatedToAgreement
/ us-gaap_CounterpartyNameAxis
= mgnx_TakedaPharmaceuticalMember
/ us-gaap_TypeOfArrangementAxis
= mgnx_ResearchCollaborationAndLicenseOptionAgreementMember
 
Research and development services revenue   $ 300,000mgnx_ResearchAndDevelopmentServicesRevenue
/ us-gaap_CounterpartyNameAxis
= mgnx_TakedaPharmaceuticalMember
/ us-gaap_TypeOfArrangementAxis
= mgnx_ResearchCollaborationAndLicenseOptionAgreementMember